glp-1 pancreatitis class action in kentucky Risk of pancreatic cancer associated with receptor agonist therapy Weight Loss Drugs Lawsuit |

In addition, weight loss is a consistent finding in clinical trials investigating GLP-1RAs ( Reduction of hepatic and adipose tissue insulin resistance An improved insulin sensitivity is expected after chronic treatment with GLP-RAs mainly due to marked bodyweight reductions

Hot flashes are more than just an annoyance

Furthermore, GLP-1RA treatment in patients with T2DM has been linked to decreased secretion of pro-inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor- (TNF-) by peripheral blood mononuclear cells (PBMC) [75]

Weight loss was initially observed as a side effect of GLP-1 medications in clinical trials testing the drugs for type 2 diabetes

95%CI 0.870.97), CV death (0.88